Stock Markets September 3, 2026 05:15 AM

Premarket: Snowflake and Five Below Lead Gains After Upside Earnings; Broadcom, HPE Slide

Futures tick higher as strong corporate results lift select names, while supply constraints and a failed drug trial weigh on others

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
AVGO FIVE RARE HPE SNOW

U.S. equity futures were mixed early Thursday after major indexes ended a three-day losing streak. Snowflake surged in premarket trading following better-than-expected results and an upgraded product revenue target. Five Below also jumped after a robust quarter and an expanded buyback plan. Hewlett Packard Enterprise and Broadcom lost ground despite positive elements in their reports, and Ultragenyx plunged after a failed late-stage drug trial.

Premarket: Snowflake and Five Below Lead Gains After Upside Earnings; Broadcom, HPE Slide
AVGO FIVE RARE HPE SNOW
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Snowflake surged over 23% in premarket trading after beating Q2 estimates (adjusted EPS $0.62 vs $0.45) and raising fiscal 2027 product revenue guidance to $6.07 billion from $5.84 billion; revenue rose 35% to $1.55 billion and product revenue rose 37% to $1.49 billion.
  • Five Below gained about 4% after reporting adjusted EPS of $1.68 versus $1.33 estimates, net sales up 22.9% to $1.26 billion, comparable sales growth of 14.1%, a raised full-year sales guide of $5.63-$5.71 billion, and a $600 million buyback authorization.
  • Hewlett Packard Enterprise and Broadcom shares fell despite positive elements in their reports; HPE cited supply constraints despite adjusted EPS of $1.11 and revenue of $12.21 billion, while Broadcom forecast Q4 revenue of $34.8 billion below estimates but outlined longer-term revenue targets and $21.7 billion in expected Q4 AI chip sales.

U.S. equity futures displayed a mixed tone early Thursday, a day after the main averages halted a three-day slide that had been driven by rising Treasury yields amid renewed U.S.-Iran hostilities. S&P 500 futures were up 0.1%, Dow futures rose 0.2%, and Nasdaq 100 futures climbed 0.1% as markets opened into the new trading day.

Several corporate reports dominated premarket activity, producing sharp moves in individual stocks.


Snowflake drew the most attention, with shares jumping more than 23% in premarket trading after the cloud-data company reported second-quarter results that exceeded expectations and raised its full-year outlook. The company posted adjusted earnings of $0.62 per share, above consensus estimates of $0.45. Revenue increased 35% year-over-year to $1.55 billion, while product revenue rose 37% to $1.49 billion, marking a third consecutive quarter of accelerating product growth.

Snowflake also lifted its fiscal 2027 product revenue guidance to $6.07 billion, up from the prior projection of $5.84 billion.


Five Below also saw meaningful gains, with shares climbing about 4% after the retailer reported a fiscal second quarter that beat expectations across key metrics. Adjusted earnings per share were $1.68, compared with estimates of $1.33. Net sales increased 22.9% to $1.26 billion, and comparable sales grew 14.1% — the company’s fifth straight quarter of double-digit comparable-store growth. Management raised full-year sales guidance to a range of $5.63 billion to $5.71 billion and authorized a new $600 million share buyback program.


Hewlett Packard Enterprise shares fell nearly 3% despite posting a quarter that beat expectations and raising guidance for fiscal 2026 and 2027. The company reported adjusted earnings of $1.11 per share on revenue of $12.21 billion, topping estimates of $0.92 and $11.93 billion, respectively. Investors focused on ongoing supply constraints even as HPE expanded its collaboration with Oracle, granting Oracle an option to purchase HPE common stock and extending Juniper networking services across Oracle’s data centers. CEO Antonio Neri said AI is "becoming a multi-year growth driver" for the company.


Broadcom shares dipped around 3% after management forecast fourth-quarter revenue of $34.8 billion, below estimates of $35.05 billion. The decline was partly offset by long-term projections from CEO Hock Tan, who said revenue would rise to $115 billion in fiscal 2027 and then double to $230 billion in fiscal 2028. Broadcom also forecast fourth-quarter AI chip sales of $21.7 billion, a figure described in the report as slightly above analysts' estimates.


Ultragenyx Pharmaceutical plunged more than 44% after announcing that its drug apazunersen did not meet the primary endpoint in a late-stage trial for Angelman syndrome, a neurodevelopmental disorder. The company said the therapy produced no meaningful improvement in cognitive ability or overall development compared with placebo and that it is reviewing the future of the program.


Overall, the morning’s activity reflected a bifurcated market: a handful of companies delivered results that materially exceeded expectations and were rewarded with sharp premarket gains, while other companies encountering supply issues, conservative quarterly forecasts, or clinical setbacks saw steep declines.

Below are concise takeaways and considerations for market participants.

  • Earnings leadership: Snowflake and Five Below led moves higher after delivering beats and raising guidance or capital-return plans.
  • Supply and execution concerns: HPE’s results were solid on the numbers yet shares fell on supply constraint commentary and investor focus on operational friction.
  • Clinical and product risk: Ultragenyx’s failed trial represents a significant program setback, reflected in the stock’s sharp decline.

Market participants will continue parsing quarterly disclosures and management commentary for signals on revenue durability, supply-chain normalization, AI-related demand, and the outlook for capital returns. The premarket moves underscore how company-level outcomes can drive pronounced stock dispersion even as broader futures show only modest changes.

Risks

  • Ongoing supply constraints at HPE that may continue to weigh on the stock despite beat-and-raise results - impacts technology hardware and networking sectors.
  • Clinical development failure at Ultragenyx for apazunersen, which led to a share plunge and raises uncertainty about the program's future - impacts biotech and pharmaceutical sectors.
  • Near-term revenue guidance miss at Broadcom for the fourth quarter, which triggered share weakness even as longer-term targets were raised - impacts semiconductor and AI chip markets.

More from Stock Markets

Legrand Shares Rise After Dual Analyst Upgrades and Strong H1 Results Sep 3, 2026 Intercos Shares Slide After Large ABB by L Catterton Vehicle Sep 3, 2026 Indian Markets Slip as Nifty Drops to One-Month Low; IT, FMCG and Healthcare Lead Declines Sep 3, 2026 UBS Identifies Four Ways to Play an Emerging European Earnings Recovery Sep 3, 2026 Barclays Urges Caution Into September as Market Headwinds Reappear Sep 3, 2026